

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/250419 A2

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 37/06* (2006.01)
A61P 35/00 (2006.01) *A61K 39/395* (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/GB2021/051452

(22) International Filing Date:

11 June 2021 (11.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2008860.5 11 June 2020 (11.06.2020) GB

(71) Applicants: **OXFORD UNIVERSITY INNOVATION LIMITED** [GB/GB]; Buxton Court, 3 West Way, Oxford OX2 0JB (GB). **MIROBIO LIMITED** [GB/GB]; Winchester House, Heatley Road, Oxford Science Park, Oxford OX4 4GE (GB).

(72) Inventors: **DAVIS, Simon John**; The MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headley Way, Oxford Oxfordshire OX3 9DS (GB). **CORNALL, Richard John**; Nuffield Department of Medicine, University of Oxford, Henry Wellcome Building for Molecular Physiology, Old Road Campus, Headington, Oxford Oxfordshire OX3 7BN (GB). **PALUCH, Christopher Douglas**; MiroBio Limited, Winchester House, Heatley Road, Oxford Science Park, Oxford Oxfordshire OX4 4GE (GB).

(74) Agent: **HGF LIMITED**; Document Handling - HGF (Manchester), 1 City Walk, LEEDS Yorkshire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: BTLA ANTIBODIES

(57) Abstract: This invention relates generally to antibodies that bind to human B and T lymphocyte attenuator (BTLA) and uses thereof. More specifically, the invention relates to agonistic antibodies that bind human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders. Suitably, the antibodies also possess an Fc modification that enhances signalling through FcγR2B.

WO 2021/250419 A2